JPMorgan Chase & Co. Cuts Oculis (NASDAQ:OCS) Price Target to $20.00

Posted by on Aug 14th, 2026

Oculis (NASDAQ:OCS – Get Free Report) had its target price dropped by equities researchers at JPMorgan Chase & Co. from $23.00 to $20.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 55.35% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. Stifel Nicolaus cut their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Needham & Company LLC dropped their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Guggenheim decreased their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Oculis in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Check Out Our Latest Report on Oculis

Oculis Stock Up 0.4%

Oculis stock traded up $0.05 during mid-day trading on Friday, hitting $12.87. The company had a trading volume of 63,967 shares, compared to its average volume of 477,171. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $12.16 and a 200 day moving average of $21.90. The stock has a market cap of $746.43 million, a price-to-earnings ratio of -7.39 and a beta of 0.51. Oculis has a 1 year low of $10.52 and a 1 year high of $34.47.

Oculis (NASDAQ:OCS – Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The firm had revenue of $0.38 million during the quarter. On average, sell-side analysts expect that Oculis will post -2.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares in the last quarter. Koshinski Asset Management Inc. acquired a new position in shares of Oculis in the 1st quarter worth approximately $238,000. Millennium Management LLC bought a new stake in shares of Oculis in the 4th quarter valued at approximately $312,000. Marshall Wace LLP acquired a new stake in shares of Oculis during the 2nd quarter valued at approximately $393,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Oculis during the 4th quarter valued at approximately $499,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

(Get Free Report)

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

Read More

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.